Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Terns Pharmaceuticals (TERN) Capital Expenditures (2020 - 2023)

Terns Pharmaceuticals (TERN) has disclosed Capital Expenditures for 4 consecutive years, with $44000.0 as the latest value for Q4 2023.

  • For the quarter ending Q4 2023, Capital Expenditures rose 29.41% year-over-year to $44000.0, compared with a TTM value of $52000.0 through Dec 2023, down 81.09%, and an annual FY2024 reading of $42000.0, down 19.23% over the prior year.
  • Capital Expenditures was $44000.0 for Q4 2023 at Terns Pharmaceuticals, up from $8000.0 in the prior quarter.
  • Across five years, Capital Expenditures topped out at $430000.0 in Q1 2020 and bottomed at -$8000.0 in Q3 2022.
  • Average Capital Expenditures over 4 years is $89357.1, with a median of $43000.0 recorded in 2021.
  • The sharpest move saw Capital Expenditures surged 1380.0% in 2021, then plummeted 110.81% in 2022.
  • Year by year, Capital Expenditures stood at $47000.0 in 2020, then skyrocketed by 325.53% to $200000.0 in 2021, then crashed by 83.0% to $34000.0 in 2022, then rose by 29.41% to $44000.0 in 2023.
  • Business Quant data shows Capital Expenditures for TERN at $44000.0 in Q4 2023, $8000.0 in Q3 2023, and $34000.0 in Q4 2022.